Scarica l'app Stockscreener
1.67
3.47%
-0.06
Pre-mercato:
1.67
Precedente Chiudi:
$1.73
Aprire:
$1.74
Volume 24 ore:
927.93K
Relative Volume:
0.53
Capitalizzazione di mercato:
$118.92M
Reddito:
$391.70K
Utile/perdita netta:
$-52.34M
Rapporto P/E:
-2.2267
EPS:
-0.75
Flusso di cassa netto:
$-45.92M
1 W Prestazione:
-5.11%
1M Prestazione:
+6.37%
6M Prestazione:
+281.80%
1 anno Prestazione:
+83.54%
Intervallo 1D:
$1.66
$1.76
Intervallo di 1 settimana:
$1.645
$1.87
Portata 52W:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Confronta OVID con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.67 | 123.20M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Roth Capital | Buy |
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
How Ovid Therapeutics Inc. stock performs in weak economyMarket Growth Review & Accurate Entry/Exit Alerts - ulpravda.ru
Why Ovid Therapeutics Inc. (1OT) stock stays on top picksCPI Data & Daily Momentum Trading Reports - ulpravda.ru
Published on: 2026-01-09 08:22:12 - ulpravda.ru
Is Ovid Therapeutics Inc. (1OT) stock safe for risk averse investorsWeekly Trade Report & Real-Time Volume Trigger Notifications - ulpravda.ru
Why hedge funds are buying Ovid Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - ulpravda.ru
Can Ovid Therapeutics Inc. stock hit record highs againQuarterly Investment Review & Weekly Consistent Profit Watchlists - ulpravda.ru
Will Ovid Therapeutics Inc. stock benefit from upcoming earnings reports2025 Buyback Activity & Reliable Price Action Trade Plans - ulpravda.ru
Aug Spikes: Can Ovid Therapeutics Inc 1OT stock sustain breakout momentumEarnings Overview Report & Safe Capital Growth Stock Tips - moha.gov.vn
How Ovid Therapeutics Inc. stock reacts to oil prices2026 world cup usa national team qualification goalkeepers low block defense knockout prediction statistical analysis - ulpravda.ru
Ovid Therapeutics (OVID) Price Target Increased by 22.06% to 4.23 - MSN
Is Ovid Therapeutics Inc. stock positioned well for digital economy2026 world cup usa national team round of 32 defensive leaders low block defense group prediction preview - ulpravda.ru
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Ovid Therapeutics is a buy, this analyst says - Cantech Letter
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold" - MarketBeat
Ovid Therapeutics (STU:1OT) EV-to-FCF : -2.91 (As of Dec. 26, 2025) - GuruFocus
Ovid Therapeutics (STU:1OT) EV-to-OCF : -2.91 (As of Dec. 27, 2025) - GuruFocus
Promising Penny Stocks To Watch In December 2025 - simplywall.st
FY2025 Earnings Forecast for OVID Issued By Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq
Form 424B3 Ovid Therapeutics Inc. - StreetInsider
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Ovid Therapeutics (OVID) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital - MarketBeat
Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
OVID: HC Wainwright Reiterates Buy Rating with $2.00 Price Targe - GuruFocus
HC Wainwright & Co. Reiterates Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq
Is Ovid Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
How Ovid Therapeutics Inc. (1OT) stock stacks up against competitorsWeekly Trade Report & Smart Investment Allocation Insights - Улправда
Will Ovid Therapeutics Inc. stock recover faster than peersGold Moves & Real-Time Volume Triggers - DonanımHaber
Is Ovid Therapeutics Inc. stock a smart buy before Fed meetingWatch List & Safe Entry Trade Reports - Улправда
Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy - Citeline News & Insights
Ovid’s KCC2 activator shows promising safety in early trial By Investing.com - Investing.com Nigeria
Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data - TipRanks
Ovid Therapeutics announces phase 1 results for Ov350 - marketscreener.com
Ovid Therapeutics Inc Reports Phase 1 Results for OV350 - TradingView — Track All Markets
Ovid’s KCC2 activator shows promising safety in early trial - Investing.com
Ovid Therapeutics Reports Phase 1 Results for the - GlobeNewswire
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) - The Manila Times
Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Aug Big Picture: How analysts rate Ovid Therapeutics Inc stock todayWeekly Loss Report & Technical Confirmation Alerts - moha.gov.vn
Janus Henderson Group PLC Acquires Significant Stake in Ovid The - GuruFocus
Roth Capital Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals - Investing.com Canada
Ovid Therapeutics shareholders approve increase in authorized shares and related proposals By Investing.com - Investing.com South Africa
Ovid Therapeutics Stockholders Approve Key Proposals - TipRanks
Roth Capital Initiates Coverage of Ovid Therapeutics (OVID) with Buy Recommendation - Nasdaq
Roth/MKM initiates Ovid Therapeutics stock with Buy rating on epilepsy drug - Investing.com Canada
OVID: Roth Capital Initiates Coverage with a "Buy" Rating at $3. - GuruFocus
Roth Capital Initiates Ovid Therapeutics With Buy Rating, $3 Price Target - marketscreener.com
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ovid Therapeutics Inc Azioni (OVID) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | CBFO |
Feb 26 '25 |
Sale |
0.56 |
3,902 |
2,185 |
67,973 |
| ALEXANDER MARGARET A. | President and COO |
Jan 27 '25 |
Buy |
0.73 |
6,810 |
4,971 |
34,935 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):